Cystic fibrosis related diabetes

Current Diabetes Reports

Volumn 14, Issue 8, 2014, Pages

  O'Shea, Donal ^a   O'Connell, Jean ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

CF related diabetes; Cystic fibrosis; Diabetes; Hyperglycemia; Insulin; Lung function

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

CYSTIC FIBROSIS; CYSTIC FIBROSIS RELATED DIABETES; DIABETES MELLITUS; DIET; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; REVIEW; SCREENING; COMPLICATION; INSULIN DEPENDENT DIABETES MELLITUS; MASS SCREENING; NON INSULIN DEPENDENT DIABETES MELLITUS;

CYSTIC FIBROSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; MASS SCREENING;

EID: 84901880875     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-014-0511-3     Document Type: Review

References (100)

1. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest. 2004;125(1 Suppl):1S-39.
2. McCormick J, Mehta G, Olesen HV, Viviani L, Macek M, Mehta A, et al. Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. Lancet. 2010;375:1007-13.
3. .•• Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, andmortality.Diabetes Care. 2009;32:1626-31. This paper reported data from a US CF center where early diagnosis and aggressive treatment of CFRD was associated with a significant narrowing of the gap in mortality between those CF patients with and without diabetes.
4. Yung B, Noormohamed FH, Kemp M, Hooper J, Lant AF, Hodson ME. Cystic fibrosis-related diabetes: the role of peripheral insulin resistance and beta-cell dysfunction. Diabet Med. 2002;19:221-6. (Pubitemid 34429653)
5. Costa M, Potvin S, Hammana I, Malet A, Berthiaume Y, Jeanneret A, et al. Increased glucose excursion in cystic fibrosis and its association with a worse clinical status. J Cyst Fibros. 2007;6:376-83. (Pubitemid 350028700)
6. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ. Epidemiology of cystic fibrosis-related diabetes. J Pediatr. 2005;146:681-7. (Pubitemid 40616255)
7. Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C. Glucose tolerance in patients with cystic fibrosis: five year prospective study. BMJ. 1995;311:655-9.
8. Scheuing N, Holl RW, Dockter G, Fink K, Junge S, Naehrlich L, et al. Diabetes in cystic fibrosis: multicenter screening results based on current guidelines. PLoS ONE. 2013;8:e81545.
9. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med. 2000;162(3 Pt 1):891-5.
10. O'Riordan SM, Robinson PD, Donaghue KC, Moran A. Management of cystic fibrosis-related diabetes. Pediatr Diabetes. 2008;9(4 Pt 1):338-44.
11. Finkelstein SM, Wielinski CL, Elliott GR, Warwick WJ, Barbosa J, Wu SC, et al. Diabetes mellitus associated with cystic fibrosis. J Pediatr. 1988;112:373-7. (Pubitemid 18079818)
12. Koch C, Rainisio M, Madessani U, Harms HK, Hodson ME, Mastella G, et al. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol. 2001;32:343-50. (Pubitemid 33015650)
13. Milla CE, Billings J, Moran A. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care. 2005;28:2141-4. (Pubitemid 41242458)
14. Bremer AA. The use of insulin in cystic fibrosis-related diabetes: A philosophical difference from the use of insulin in Type 1 and Type 2 diabetes. Pediatr Pulmonol. 2012;47:1039-41.
15. Kerem E, Corey M, Kerem BS, Rommens J, Markiewicz D, Levison H, et al. The relation between genotype and phenotype in cystic fibrosis-analysis of the most common mutation (delta F508). N Engl J Med. 1990;323:1517-22.
16. Hartling SG, Garne S, Binder C, Heilmann C, Petersen W, Petersen KE, et al. Proinsulin, insulin, and C-peptide in cystic fibrosis after an oral glucose tolerance test. Diabetes Res. 1988;7:165-9.
17. .•• Moran A, Becker D, Casella SJ, Gottlieb PA, Kirkman MS, Marshall BC, et al. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care. 2010;33:2677-83. A comprehensive review published at the same time as the CFRD consensus conference clinical care guidelines.
18. Hardin DS, LeBlanc A, Lukenbough S, Seilheimer DK. Insulin resistance is associated with decreased clinical status in cystic fibrosis. J Pediatr. 1997;130:948-56. (Pubitemid 27495124)
19. Austin A, Kalhan SC, Orenstein D, Nixon P, Arslanian S. Roles of insulin resistance and beta-cell dysfunction in the pathogenesis of glucose intolerance in cystic fibrosis. J Clin Endocrinol Metab. 1994;79:80-5. (Pubitemid 24221164)
20. Ahmad T, Nelson R, Taylor R. Insulin sensitivity and metabolic clearance rate of insulin in cystic fibrosis. Metabolism. 1994;43:163-7. (Pubitemid 24061847)
21. Moran A, Pyzdrowski KL, Weinreb J, Kahn BB, Smith SA, Adams KS, et al. Insulin sensitivity in cystic fibrosis. Diabetes. 1994;43:1020-6. (Pubitemid 24230707)
22. Blackman SM, Hsu S, Vanscoy LL, Collaco JM, Ritter SE, Naughton K, et al. Genetic modifiers play a substantial role in diabetes complicating cystic fibrosis. J Clin Endocrinol Metab. 2009;94:1302-9.
23. Blackman SM, Hsu S, Ritter SE, Naughton KM, Wright FA, Drumm ML, et al.A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia. 2009;52:1858-65.
24. Couce M, O'Brien TD, Moran A, Roche PC, Butler PC. Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis. J Clin Endocrinol Metab. 1996;81:1267-72. (Pubitemid 26084003)
25. Minicucci L, Cotellessa M, Pittaluga L, Minuto N, d'Annunzio G, Avanzini MA, et al. Beta-cell autoantibodies and diabetes mellitus family history in cystic fibrosis. J Pediatr Endocrinol Metab. 2005;18:755-60. (Pubitemid 41309338)
26. Gottlieb PA, Yu L, Babu S, Wenzlau J, Bellin M, Frohnert BI, et al. No relation between cystic fibrosis-related diabetes and type 1 diabetes autoimmunity. Diabetes Care. 2012;35:e57.
27. Sobrin L. Longitudinal validation of hemoglobin A(1c) criteria for diabetes diagnosis: risk of retinopathy. Diabetes. 2012;61:3074-5.
28. Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care. 2011;34:145-50.
29. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;33 Suppl 1:S62-9.
30. Chance WW, Rhee C, Yilmaz C, Dane DM, Pruneda ML, Raskin P, et al. Diminished alveolar microvascular reserves in type 2 diabetes reflect systemic microangiopathy. Diabetes Care. 2008;31:1596-601.
31. Kuziemski K, Pienkowska J, Slominski W, Specjalski K, Dziadziuszko K, Jassem E, et al. Role of quantitative chest perfusion computed tomography in detecting diabetic pulmonary microangiopathy. Diabetes Res Clin Pract. 2011;91:80-6.
32. Goldman MD. Lung dysfunction in diabetes. Diabetes Care. 2003;26:1915-8. (Pubitemid 36929143)
33. Pitocco D, Fuso L, Conte EG, Zaccardi F, Condoluci C, Scavone G, et al. The diabetic lung-a new target organ? Rev Diabet Stud. 2012;9:23-35.
34. Klein OL, Krishnan JA, Glick S, Smith LJ. Systematic review of the association between lung function and Type 2 diabetes mellitus. Diabetes Med. 2010;27:977-87.
35. Wood DM, Brennan AL, Philips BJ, Baker EH. Effect of hyperglycemia on glucose concentration of human nasal secretions. Clin Sci (Lond). 2004;106:527-33. (Pubitemid 38639557)
36. Brennan AL, Gyi KM, Wood DM, Johnson J, Holliman R, Baines DL, et al. Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. J Cyst Fibros. 2007;6:101-9. (Pubitemid 46394299)
37. Philips BJ, Meguer JX, Redman J, Baker EH. Factors determining the appearance of glucose in upper and lower respiratory tract secretions. Intensive Care Med. 2003;29:2204-10. (Pubitemid 38030673)
38. Baker EH, Clark N, Brennan AL, Fisher DA, Gyi KM, Hodson ME, et al. Hyperglycemia and cystic fibrosis alter respiratory fluid glucose concentrations estimated by breath condensate analysis. J Appl Physiol. 2007;102:1969-75. (Pubitemid 46701969)
39. Philips BJ, Redman J, Brennan A, Wood D, Holliman R, Baines D, et al. Glucose in bronchial aspirates increases the risk of respiratory MRSA in intubated patients. Thorax. 2005;60:761-4. (Pubitemid 41297896)
40. Garnett JP, Gray MA, Tarran R, Brodlie M, Ward C, Baker EH, et al. Elevated paracellular glucose flux across cystic fibrosis airway epithelial monolayers is an important factor for Pseudomonas aeruginosa growth. PLoS ONE. 2013;8:e76283.
41. Hunt WR, Zughaier SM, Guentert DE, Shenep MA, Koval M, McCarty NA, et al. Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes. Am J Physiol Lung Cell Mol Physiol. 2014;306:L43-9.
42. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106:2067-72. (Pubitemid 35192812)
43. •• Waugh N, Royle P, Craigie I, Ho V, Pandit L, Ewings P, et al. Screening for cystic fibrosis-related diabetes: a systematic review. Health Technol Assess. 2012;16:iii-iv:1-179. A comprehensive and informative review of currently recommended and potentially more appropriate screening methods for CFRD.
44. Sterescu AE, Rhodes B, Jackson R, Dupuis A, Hanna A, Wilson DC, et al. Natural history of glucose intolerance in patients with cystic fibrosis: ten-year prospective observation program. J Pediatr. 2010;156:613-7.
45. Moran A, Hardin D, Rodman D, Allen HF, Beall RJ, Borowitz D, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract. 1999;45:61-73. (Pubitemid 29356125)
46. .•• Moran A, Pekow P, Grover P, Zorn M, Slovis B, Pilewski J, et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care. 2009;32:1783-8. This study confirmed that insulin therapy improved CF-specific outcomes in CFRD without fasting hyperglycemia.
47. Rolon MA, Benali K, Munck A, Navarro J, Clement A, Tubiana-Rufi N, et al. Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy. Acta Paediatr. 2001;90:860-7. (Pubitemid 32762829)
48. .•• Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33:2697-708. The most up-to-date recommendations for clinical practice in CFRD.
49. Holl RW, Buck C, Babka C, Wolf A, Thon A. HbA1c is not recommended as a screening test for diabetes in cystic fibrosis. Diabetes Care. 2000;23:126. (Pubitemid 30022909)
50. Lee KM, Miller RJ, Rosenberg FM, Kreisman SH. Evaluation of glucose tolerance in cystic fibrosis: comparison of 50-g and 75-g tests. J Cyst Fibros. 2007;6:274-6. (Pubitemid 46971892)
51. Mueller-Brandes C, Holl RW, Nastoll M, Ballmann M. New criteria for impaired fasting glucose and screening for diabetes in cystic fibrosis. Eur Respir J. 2005;25:715-7. (Pubitemid 40528767)
52. Godbout A, Hammana I, Potvin S, Mainville D, Rakel A, Berthiaume Y, et al. No relationship between mean plasma glucose and glycated hemoglobin in patients with cystic fibrosis-related diabetes. Diabetes Metab. 2008;34(6 Pt 1):568-73.
53. Wagener JS, McNeill GC, Taussig LM, Corrigan JJ, Lemen R. Ferrokinetic and hematologic studies in cystic fibrosis patients. Am J Pediatr Hematol Oncol. 1983;5:153-60. (Pubitemid 13000266)
54. O'Riordan SM, Robinson PD, Donaghue KC, Moran A. Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes. 2009;10 Suppl 12:43-50.
55. Management of Cystic Fibrosis Related Diabetes Mellitus: Report of the UK Cystic Fibrosis Working Group. UK CF Trust; 2004.
56. Park PJ, Griffin SJ, Duffy SW, Wareham NJ. The effect of varying the screening interval on false positives and duration of undiagnosed disease in a screening programme for type 2 diabetes. J Med Screen. 2000;7:91-6.
57. Dobson L, Sheldon CD, Hattersley AT. Conventional measures underestimate glycaemia in cystic fibrosis patients. Diabetes Med. 2004;21:691-6. (Pubitemid 38916212)
58. Brodsky J, Dougherty S, Makani R, Rubenstein RC, Kelly A. Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis. Diabetes Care. 2011;34:292-5.
59. Walshaw M. Routine OGTT screening for CFRD - no thanks. J Royal Soc Med. 2009;102 Suppl 1:40-4.
60. Dobson L, Hattersley AT, Tiley S, Elworthy S, Oades PJ, Sheldon CD. Clinical improvement in cystic fibrosis with early insulin treatment. Arch Dis Child. 2002;87:430-1. (Pubitemid 35252911)
61. Moreau F, Weiller MA, Rosner V, Weiss L, Hasselmann M, Pinget M, et al. Continuous glucose monitoring in cystic fibrosis patients according to the glucose tolerance. Horm Metab Res. 2008;40:502-6.
62. Lachin JM, Orchard TJ, Nathan DM, Group DER. Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37:39-43.
63. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159-67.
64. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
65. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-65.
66. Schwarzenberg SJ, Thomas W, Olsen TW, Grover T, Walk D, Milla C, et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care. 2007;30:1056-61. (Pubitemid 46684624)
67. Andersen HU, Lanng S, Pressler T, Laugesen CS, Mathiesen ER. Cystic fibrosis-related diabetes: the presence of microvascular diabetes complications. Diabetes Care. 2006;29:2660-3. (Pubitemid 44912195)
68. Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev. 2013;7, CD004730.
69. Moran A, Phillips J, Milla C. Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care. 2001;24:1706-10. (Pubitemid 33716470)
70. Grover P, Thomas W, Moran A. Glargine vs NPH insulin in cystic fibrosis related diabetes. J Cyst Fibros. 2008;7:134-6. (Pubitemid 351372762)
71. Hardin DS, Rice J, Rice M, Rosenblatt R. Use of the insulin pump to treat cystic fibrosis related diabetes. J Cyst Fibros. 2009;8:174-8.
72. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med. 1992;326:1187-91.
73. Kerem E, Corey M, Stein R, Gold R, Levison H. Risk factors for Pseudomonas aeruginosa colonization in cystic fibrosis patients. Pediatr Infect Dis J. 1990;9:494-8. (Pubitemid 20218406)
74. Matel JL, Milla CE. Nutrition in cystic fibrosis. Semin Respir Crit Care Med. 2009;30:579-86.
75. Stack M, Mahony M, Boyle C. Obesity in childhood cystic fibrosis (Abstract 220). J Cyst Fibros. 2007;6(Suppl):S54.
76. Kastner-Cole D, Palmer CN, Ogston SA, Mehta A, Mukhopadhyay S. Overweight and obesity in deltaF508 homozygous cystic fibrosis. J Pediatr. 2005;147:402-4. (Pubitemid 41345776)
77. Panagopoulou P, Fotoulaki M, Nikolaou A, Nousia-Arvanitakis S. Prevalence of malnutrition and obesity among cystic fibrosis patients. Pediatr Int. 2014;56:89-94.
78. Stephenson AL, Mannik LA, Walsh S, Brotherwood M, Robert R, Darling PB, et al. Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study. Am J Clin Nutr. 2013;97:872-7.
79. Coderre L, Fadainia C, Belson L, Belisle V, Ziai S, Maillhot G, et al. LDL-cholesterol and insulin are independently associated with body mass index in adult cystic fibrosis patients. J Cyst Fibros. 2012;11:393-7.
80. Collins S, Reynolds F. How do adults with cystic fibrosis cope following a diagnosis of diabetes? J Adv Nurs. 2008;64:478-87.
81. Dashiff C, Suzuki-Crumly J, Kracke B, Britton L, Moreland E. Cystic fibrosis-related diabetes in older adolescents: parental support and self-management. J Spec Pediatr Nurs. 2013;18:42-53.
82. Tierney S, Deaton C, Webb K, Jones A, Dodd M, McKenna D, et al. Isolation, motivation and balance: living with type 1 or cystic fibrosis-related diabetes. J Clin Nurs. 2008;17:235-43.
83. Aschner P, LaSalle J, McGill M. Global Partnership for Effective Diabetes M. The team approach to diabetes management: partnering with patients. Int J Clin Pract Suppl. 2007;157:22-30. (Pubitemid 350076257)
84. Swartz LM, Laffel LM. A teenage girl with cystic fibrosis-related diabetes, diabetic ketoacidosis, and cerebral edema. Pediatr Diabet. 2008;9(4 Pt 2):426-30.
85. Eenkhoorn V, Van den Driessche A, Van Gaal L, Desager K, De Block C. Diabetic keto-acidosis as a presentation of cystic fibrosis-related diabetes: a case report. J Diabetes Complications. 2011;25:137-41.
86. Tierney S, Webb K, Jones A, Dodd M, McKenna D, Rowe R, et al. Living with cystic fibrosis-related diabetes or type 1 diabetes mellitus: a comparative study exploring health-related quality of life and patients' reported experiences of hypoglycaemia. Chronic Illn. 2008;4:278-88.
87. Radike K, Molz K, Holl RW, Poeter B, Hebestreit H, Ballmann M. Prognostic relevance of hypoglycemia following an oral glucose challenge for cystic fibrosis-related diabetes. Diabetes Care. 2011;34:e43.
88. van den Berg JM, Morton AM, Kok SW, Pijl H, Conway SP, Heijerman HG. Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD). J Cyst Fibros. 2008;7:515-9.
89. Yung B, Landers A, Mathalone B, Gyi KM, Hodson ME. Diabetic retinopathy in adult patients with cystic fibrosis-related diabetes. Respir Med. 1998;92:871-2. (Pubitemid 28360617)
90. Dobson L, Stride A, Bingham C, Elworthy S, Sheldon CD, Hattersley AT. Microalbuminuria as a screening tool in cystic fibrosis-related diabetes. Pediatr Pulmonol. 2005;39:103-7. (Pubitemid 40205044)
91. Guman-Wignot TM, Kaufman J, Holsclaw Jr DS, Schmoyer IR, Alhadeff JA. Analysis and HPLC fractionation of urine from patients with cystic fibrosis, chronic lung diseases and normal controls. Clin Biochem. 1989;22:377-83. (Pubitemid 19256228)
92. Lanng S, Thorsteinsson B, Nerup J, Koch C. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr. 1992;151:684-7.
93. Kerem E, Viviani L, Zolin A, Macneill S, Hatziagorou E, Ellemunter H, et al. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS Patient Registry. Eur Respir J. 2014;43:125-33.
94. Alicandro G, Battezzati PM, Battezzati A, Speziali C, Claut L, Motta V, et al. Insulin secretion, nutritional status and respiratory function in cystic fibrosis patients with normal glucose tolerance. Clin Nutr. 2012;31:118-23.
95. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med. 2000;162(3 Pt 1):891-5.
96. Leclercq A, Gauthier B, Rosner V, Weiss L, Moreau F, Constantinescu AA, et al. Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients. J Cyst Fibros. 2013;S1569-993. [Epub ahead of print].
97. Brennan AL, Gyi KM, Wood DM, Johnson J, Holliman R, Baines DL, et al. Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. J Cyst Fibros. 2007;6:101-9. (Pubitemid 46394299)
98. Mohan K, Israel KL, Miller H, Grainger R, Ledson MJ, Walshaw MJ. Long-term effect of insulin treatment in cystic fibrosis-related diabetes. Respiration. 2008;76:181-6.
99. Kolouskova S, Zemkova D, Bartosova J, Skalicka V, Sumnik Z, Vavrova V, et al. Low-dose insulin therapy in patients with cystic fibrosis and early-stage insulinopenia prevents deterioration of lung function: a 3-year prospective study. J Pediatr Endocrinol Metab. 2011;24(7-8):449-54.
100. Mozzillo E, Franzese A, Valerio G, Sepe A, De Simone I, Mazzarella G, et al. One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements. Pediatr Diabetes. 2009;10:162-7.